<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03349892</url>
  </required_header>
  <id_info>
    <org_study_id>Cardiac SABR</org_study_id>
    <nct_id>NCT03349892</nct_id>
  </id_info>
  <brief_title>Stereotactic Ablative Radiotherapy for Refractory Ventricular Tachycardia</brief_title>
  <official_title>Stereotactic Ablative Radiotherapy (SABR) for Refractory Ventricular Tachycardia - a Phase I/II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, Los Angeles</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Single arm, phase Ib/2a dose escalation study with an expansion cohort to determine the
      maximal tolerated dose (MTD) for stereotactic ablative radiotherapy of targets in the cardiac
      myocardium and to make a preliminary assessment of the efficacy of the treatment. The dose
      escalation will be guided by Time-to-Event Continual Reassessment Method (TITE-CRM) to ensure
      more patients will be spared dose limiting toxicities and more patients will be entered on
      the dose level that will be chosen as minimal dose of maximal effect. This design also allows
      for continual accrual of patients when delayed adverse events may be observed.
    </textblock>
  </brief_summary>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Pending FDA Directives
  </why_stopped>
  <start_date type="Actual">April 1, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ICD (implantable cardioverter defibrillator) shock free survival</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of salvage definitive anti-arrhythmia therapy (cardiac transplant)</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of return of ventricular tachycardia requiring defibrillation, intravenous drug therapy or readmission to hospital</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of ICD shocks</measure>
    <time_frame>12 months post-SABR procedure</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Incidence of decline of LV ejection fraction by more than 5% on two consecutive echocardiograms</measure>
    <time_frame>5 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of persistent increase in baseline supplemental oxygen requirement by 1L for a duration of &gt;3 months</measure>
    <time_frame>5 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of steroid use for radiotherapy related indications</measure>
    <time_frame>5 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Overall survival</measure>
    <time_frame>Followed for 10 years +</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Quality of life, as assessed by the short-form 36 (SF-36) questionnaire</measure>
    <time_frame>5 years</time_frame>
  </other_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Refractory Ventricular Tachycardia</condition>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Stereotactic Ablative Radiotherapy (SABR)</intervention_name>
    <description>A single fraction of radiation is delivered using a clinical radiotherapy system capable of stereotactic radiotherapy to the chest, with on-board image guided radiotherapy capabilities, respiratory motion management, and Intensity Modulated Radiotherapy Treatment (IMRT) planning.</description>
    <other_name>external beam radiation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Documented sustained ventricular arrhythmias refractory to or not a suitable candidate for
        catheter based RFA ablative therapy

          -  Documented sustained ventricular arrhythmias refractory to or not a suitable candidate
             for cardiac sympathetic denervation therapy

          -  Documented ventricular arrhythmias refractory to or not a suitable candidate for
             cardiac transplantation

          -  Documented sustained ventricular arrhythmias refractory to or not a suitable candidate
             for additional medical management

          -  ICD in place with documented episodes recurrent VT despite best clinical management
             previous refusal of ICD with recurrent sustained ventricular arrhythmias

          -  If ischemic cardiomyopathy, myocardial infarction occurred more than one month prior
             to enrollment

          -  No history of prior radiotherapy to the chest

          -  Prescribed dose must be deliverable using SABR technique

          -  Age â‰¥ 18 years

          -  Karnofsky Performance Status (KPS) &gt; 70

          -  If a woman is of childbearing potential, a negative serum pregnancy test must be
             documented. Women of childbearing potential must agree to use adequate contraception
             (hormonal or barrier method of birth control; or abstinence) for at least 4 weeks
             after study treatment.

          -  Ability to understand and willingness to sign a written informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of California, Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 17, 2017</study_first_submitted>
  <study_first_submitted_qc>November 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 22, 2017</study_first_posted>
  <last_update_submitted>April 11, 2018</last_update_submitted>
  <last_update_submitted_qc>April 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Los Angeles</investigator_affiliation>
    <investigator_full_name>Robert K. Chin</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tachycardia</mesh_term>
    <mesh_term>Tachycardia, Ventricular</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

